U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07313800) titled 'EMBRACE: Middle Meningeal Artery Embolization for Refractory Episodic Migraine' on Dec. 30, 2025.
Brief Summary: This single-site, open-label pilot study evaluates bilateral middle meningeal artery (MMA) coil embolization using FDA-cleared coils in adults aged 18-60 with refractory migraine (at least 8 headache days per month despite failing 2 or more preventive medications).
Participants first undergo bilateral MMA lidocaine testing during diagnostic angiography to assess short-term response. Those showing a positive response (>=50% reduction in headache intensity or frequency) proceed to bilateral MMA coil embolization.
The study...